Recent Posts
- OX2 Reaches Recommended Phase 2 Dose Milestone in Pediatric Brain Tumor Trial
- Vaccine Trial Launched to Fight Pediatric Brain Cancer
- New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
- FDA Grants IND Approval to OX2 Therapeutics to Initiate Phase I Clinical Trial of Its Peptide Checkpoint Modulator for Patients with CNS Tumors
Categories
- Featured (2)
- News Story (2)
- Press Release (2)